Association of IGF‐1 and IGFBP‐3 levels with gastric cancer: A systematic review and meta‐analysis

Abstract

Purpose:Many studies have investigated the association between serum IGF-1 and IGFBP levels with gastric cancer (GC), but the results remained inconclusive. In this work, we performed a systematic review and meta-analysis to examine the precise association of serum levels of IGF-1 and IGFBP with GC.Methods:A comprehensive systematic search was carried out in PubMed/MEDLINE, SCOPUS, Web of Science, and EMBASE databases for (nested) case-control studies that reported the levels of IGF-1 and IGFBP in GC cases and healthy controls, from inception until October 2020. Weighted mean difference (WMD) was calculated for estimating combined effect size. Subgroup analysis was performed to identify the source of heterogeneity among studies. Results:We found eight and five eligible studies (with 1541 participants) which provided data for IGF-1 and IGFBP, respectively. All studies on IGFBP reported the IGFBP-3 isoform. The pooled results indicate that GC patients had significantly lower serum IGF-1 [WMD = −26.21 ng/mL (95% CI, −45.58 to −6.85; P = .008)] and IGFBP-3 [WMD = −0.41 ng/mL (95% CI, −0.80 to −0.01; P = .04; I 2 = 89.9%; P < .001)] levels than those in healthy subjects. Significant heterogeneity was observed in the association, which could be attributed to the sample size of the studies. Conclusions:In conclusion, our study reveals a significantly lower level of IGF-1 and IGFBP-3 in GC patients compared with healthy control subjects.

Serum insulin-like growth factor binding protein 3 as a promising diagnostic and prognostic biomarker in esophagogastric junction adenocarcinoma

“…Many previous studies suggested that the alteration of IGFBP3 could affect many types of tumors including hepatocellular carcinoma [ 19 ], breast cancer [ 20 ], and lung cancer [ 21 ]. A study revealed that compared with healthy subjects, the level of serum IGFBP3 in patients with gastric cancer decreased significantly [ 22 ]. However, what the role of IGFBP3 is in EJA has not been reported.…”

IGF-1 and IGF-2 as Molecules Linked to Causes and Consequences of Obesity from Fetal Life to Adulthood: A Systematic Review

“…Research indicates that elevated serum IGF-1 levels are associated with an increased risk of multiple cancers. However, it has been observed that patients with gastric cancer have lower serum IGF-1 levels than healthy patients, which contradicts previously reported information about the IGF pathway [101]. It is a potent mitogen that has an antiapoptotic function and promotes the formation of cancer metastases [5].…”

Diabetes Mellitus and Gastric Cancer: Correlation and Potential Mechanisms

“…Overexpression of IGFBP-1 inhibits MMP-9-induced GC cell migration and protects against H. pylori-induced GC [80]. Although clinical studies have shown that IGFBP-3 can be used as a biomarker for the diagnosis and prognosis of esophageal gastric junction adenocarcinoma [81] and that the simultaneous decrease of IGFBP-3 and increase of IGF-I may promote tumor growth Journal of Diabetes Research [82], the mechanism underlying the relationship between these two potential biomarkers and GC has not been established. IGFBP-5 overexpression promotes the activity of the tumor suppressor factor PKNOX2, which can limit the development of GC [83].…”